Oppenheimer analysts adjusted their outlook on Ingredion stock (NYSE: NYSE:INGR), reducing the price target from $178.00 to $167.00, while maintaining an Outperform rating. The modification follows a ...

Christopher Nolan’s next project is an adaptation of The Odyssey, and though Oppenheimer is his biggest project to date, his ...

Oppenheimer (NYSE:OPY – Get Free Report) was downgraded by equities research analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a report issued on Monday. Oppenheimer Trading ...

Oppenheimer raised the firm’s price target on Enphase Energy (ENPH) to $103 from $101 and keeps an Outperform rating on the shares. Despite a ...

Alphabet (GOOGL) will be stepping up to the earnings plate tomorrow (February 4), when it will deliver its fourth quarter ...

The card collecting industry has exploded in recent years to such an extent that industry leader Topps is now producing a Robert Oppenheimer card that's ...

(JTA) — Friday is not just “Barbie” release day — moviegoers are also planning to fill theaters across the United States to see Christopher Nolan’s “Oppenheimer” biopic. Many hope it ...

YAVNE, Israel, Feb. 04, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics ...

Benny Safdie is the latest actor to join the cast of The Odyssey, the next movie from Christopher Nolan, according to The ...

Oppenheimer downgraded Apple from "outperform" to "perform" because it is struggling to adapt to a competitive AI landscape.

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and present ...

U.K. home entertainment hits record $6.4 billion as 'Wonka' leads formats, with streaming and 'Dune 2,' 'Oppenheimer' driving ...